Condition: Thromboembolus · Massive Blood Transfusion; Thrombocytopenia · Trauma · Sponsor: Zeliha Alicikus
This study aims to compare the incidence of thromboembolic complications among trauma patients receiving PCC, rFVIIa, both agents, or neither during massive transfusion. Secondary objectives include comparing mortality, transfusion requirements, intensive care unit (ICU) and hospital length of stay, ventilator-free days, and the incidence of transfusion-associated adverse events such as transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO). Subgroup analyses will evaluate outcomes in patients with and without laboratory-confirmed TIC (INR \>1.2).
This description comes directly from the study's public registry record.
Ayten SARAÇOĞLU, Prof,MD · +1 (904) 524-4331 · anesthesiayten@gmail.com
Tolga SARAÇOĞLU, Prof,MD · +1 (904) 524-5932 · kemaltolgasaracoglu@gmail.com
Always discuss trial participation with your own doctor first.
| UF Health Jacksonville (Shands Hospital) | Jacksonville, Florida, United States | Recruiting |
| UF Health Jacksonville (Shands Hospital) | Jacksonville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07290634